SRP-1003 for Myotonic Dystrophy

This trial explores a new treatment called SRP-1003 for individuals with type 1 myotonic dystrophy (DM1), a condition that causes muscle weakness and stiffness. The study aims to assess the safety and tolerability of the treatment compared to a placebo, involving different doses administered either by IV or injection. Individuals diagnosed with DM1, who show clear signs of muscle stiffness and can walk independently for at least 10 meters, might be suitable candidates for this trial. As a Phase 1/Phase 2 trial, this research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.

Research shows that SRP-1003, the treatment under study, is being tested for safety and tolerance in people with type 1 myotonic dystrophy (DM1). Early results from past studies suggest that the treatment is generally well-tolerated. Specifically, when administered as an injection under the skin, most participants did not experience severe side effects.

When given through an IV (a drip into a vein), some studies reported mild to moderate side effects in some participants. These side effects are not unusual and can usually be managed. Overall, both methods of administering SRP-1003—by IV or injection under the skin—appear to be tolerated fairly well, based on current information.

Unlike the standard treatments for myotonic dystrophy, which mostly aim to manage symptoms, SRP-1003 targets the root cause of the disease. Researchers are excited about this treatment because it employs a novel mechanism of action designed to directly modify the genetic issue responsible for the condition. Additionally, SRP-1003 offers flexible delivery options, available as both an intravenous (IV) infusion and a subcutaneous (SC) injection, potentially providing more convenience and accessibility for patients. This innovative approach has the potential to offer more effective and long-lasting benefits compared to existing therapies.

Research shows that SRP-1003 targets and reduces a specific protein in muscles called myotonic dystrophy protein kinase (DMPK). This is crucial because DMPK is linked to the symptoms of type 1 myotonic dystrophy (DM1). In earlier animal studies, a similar method reduced DMPK in muscles by over 80% for more than 85 days. These findings suggest that SRP-1003 could help lessen the harmful effects of DMPK in people with DM1. Although human studies have provided limited information, these early results are promising for SRP-1003's potential to treat DM1. Participants in this trial will receive either SRP-1003 or a placebo, administered by intravenous (IV) infusion or subcutaneous (SC) injection.²⁶⁷⁸⁹